I can’t help it. This reminds me of the movie City Slickers, in which one of the characters has messed up his life, and his friends tell him he’s getting a “do-over.” The young company Dance Pharmaceuticals, based in downtown San Francisco, is basically on a mission to salvage the good parts of Pfizer’s failed inhaled insulin Exubera (not the awkward delivery device!) and launch a second coming of the base product that is “simpler,…Read more »
Last week, thousands of healthcare companies and investors therein descended upon San Francisco for the 2011 JP Morgan Healthcare Conference. Although I wasn’t able to attend personally, I’ve been keeping an eagle eye on what happened there in terms of diabetes through my friend, seasoned industry observer David Kliff of Diabetic Investor — reporting daily on what he calls “the wacky world of diabetes devices.”
He’s kindly given me permission to summarize some of his…
Happy New Year, everyone! I’ve been mostly off-line this past week, attempting to enjoy the “break” while cleaning and sorting out our fresh-from-construction home. But even in that daze, I couldn’t help noticing all the fuss about MannKind’s Afrezza, which was supposed to be ruled upon by the FDA on Dec. 29.
The FDA has requested an additional four weeks to make a decision on this new inhalable insulin, after having postponed the decision by…
MannKind Corp., the most aggressive company pushing ahead on bringing inhalable insulin to market post the Exubera debacle, took a hit last week when it was forced to announce that a critical marketing partnership didn’t pan out. Investors are now fighting over the company’s future.
As a PWD who watched the whole sordid Exubera story play out with a sad smirk on my face (we all knew the product was too clunky and hard to…Read more »